Literature DB >> 25433430

Incretin-based therapies and pancreatitis risk: myth or reality.

Joseph M Pappachan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25433430     DOI： 10.1007/s12020-014-0490-9

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  21 in total

1.  Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents.

Authors:  Krystyna Tatarkiewicz; Pamela A Smith; Emmanuel J Sablan; Clara J Polizzi; Donald E Aumann; Christiane Villescaz; Diane M Hargrove; Bronislava R Gedulin; Melissa G W Lu; Lisa Adams; Tina Whisenant; Denis Roy; David G Parkes
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-10-05       Impact factor: 4.310

2.  Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  S E Inzucchi; R M Bergenstal; J B Buse; M Diamant; E Ferrannini; M Nauck; A L Peters; A Tsapas; R Wender; D R Matthews
Journal:  Diabetologia       Date:  2012-04-20       Impact factor: 10.122

3.  Standards of medical care in diabetes--2014.

Authors: 
Journal:  Diabetes Care       Date:  2014-01       Impact factor: 19.112

4.  Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database.

Authors:  Jean-Luc Faillie; Samy Babai; Sabrina Crépin; Virginie Bres; Marie-Laure Laroche; Hervé Le Louet; Pierre Petit; Jean-Louis Montastruc; Dominique Hillaire-Buys
Journal:  Acta Diabetol       Date:  2013-12-19       Impact factor: 4.280

Review 5.  Extra-pancreatic effects of incretin-based therapies.

Authors:  Baptist Gallwitz
Journal:  Endocrine       Date:  2014-03-07       Impact factor: 3.633

Review 6.  Inflammation, autophagy, and obesity: common features in the pathogenesis of pancreatitis and pancreatic cancer.

Authors:  Ilya Gukovsky; Ning Li; Jelena Todoric; Anna Gukovskaya; Michael Karin
Journal:  Gastroenterology       Date:  2013-06       Impact factor: 22.682

Review 7.  Biology of incretins: GLP-1 and GIP.

Authors:  Laurie L Baggio; Daniel J Drucker
Journal:  Gastroenterology       Date:  2007-05       Impact factor: 22.682

Review 8.  Should we still be concerned about the potential side effects of glucagon-like peptide-1 receptor agonists on thyroid C cells?

Authors:  Yang Cao; Xiao-Min Liu
Journal:  Endocrine       Date:  2014-07-18       Impact factor: 3.633

9.  Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.

Authors:  Belinda Gier; Aleksey V Matveyenko; David Kirakossian; David Dawson; Sarah M Dry; Peter C Butler
Journal:  Diabetes       Date:  2012-01-20       Impact factor: 9.461

10.  A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?

Authors:  Peter C Butler; Michael Elashoff; Robert Elashoff; Edwin A M Gale
Journal:  Diabetes Care       Date:  2013-05-03       Impact factor: 19.112
View more
  2 in total

Review 1.  Medical Management of Diabesity: Do We Have Realistic Targets?

Authors:  Joseph M Pappachan; Ananth K Viswanath
Journal:  Curr Diab Rep       Date:  2017-01       Impact factor: 4.810

2.  Incretin manipulation in diabetes management.

Authors:  Joseph M Pappachan; A V Raveendran; Rajagopalan Sriraman
Journal:  World J Diabetes       Date:  2015-06-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.